<DOC>
	<DOC>NCT00492570</DOC>
	<brief_summary>This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.</brief_summary>
	<brief_title>GER-009-06-AVX Early Therapy in Multiple Sclerosis</brief_title>
	<detailed_description>This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis treatment with DMT during the last 12 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Cognitive Dysfunction in Multiple sclerosis</keyword>
	<keyword>early treatment</keyword>
	<keyword>Avonex</keyword>
	<keyword>interferon beta 1a</keyword>
	<keyword>Cognitive Dysfunction</keyword>
</DOC>